Trial Information

Preventing the Recurrence of Depression in Bipolar Disorder

This study compares combination treatment with a mood stabilizer plus an antidepressant to treatment with the mood stabilizer alone and to gather information about the safety, tolerability and frequency of mood changes during continuation treatment. The purpose is to collect information about whether the combination treatment results in fewer returns of depressive symptoms compared to treatment with the mood stabilizer alone. Both study drugs are FDA-approved. Study participation can last up to 62 weeks.

Inclusion Criteria

Men and women
18 years of age or older
Diagnosis of bipolar disorder, currently experiencing a depressive episode
Able to read, write and understand English

Exclusion Criteria

Current alcohol or drug abuse, or alcohol or drug dependence within the past 3 months
Known sensitivity to (or unable to take) either study drug
Unstable medical condition or use of certain other medications
Pregnant or nursing women, or women of child-bearing potential who are unwilling to use a medically acceptable form of contraception
Actively suicidal or requiring hospitalization

Linda Skaggs
Rush University Medical Center - Treatment Research Center
1700 W. Van Buren Street, 5th Floor
Chicago, IL 60612
Phone: 312-980-6356
Fax: 312-942-2177
Email: Linda_M_Skaggs@rush.edu

View Map

Research Center Information: Rush University Medical Center - Treatment Research Center

If you would like to learn more about participating in this study, please send an email message using the form below.

Name:
Address:
City:
State:
Country:
Phone:
Email:
Message:

DISCLAIMER: This site is run by CenterWatch, a publishing company that focuses on the clinical trials industry. The information provided in this service is designed to help patients find clinical trials that may be of interest to them, and to help patients contact the centers conducting the research. CenterWatch is neither promoting this research nor involved in conducting any of these trials.